0000899243-22-020055.txt : 20220527
0000899243-22-020055.hdr.sgml : 20220527
20220527212742
ACCESSION NUMBER: 0000899243-22-020055
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220525
FILED AS OF DATE: 20220527
DATE AS OF CHANGE: 20220527
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCLAUGHLIN JOHN PETER
CENTRAL INDEX KEY: 0001277967
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39473
FILM NUMBER: 22980140
MAIL ADDRESS:
STREET 1: C/O PDL BIOPHARMA, INC.
STREET 2: 932 SOUTHWOOD BOULEVARD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LENSAR, Inc.
CENTRAL INDEX KEY: 0001320350
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 320125724
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2800 DISCOVERY DRIVE
STREET 2: SUITE 100
CITY: ORLANDO
STATE: FL
ZIP: 32826
BUSINESS PHONE: 888-536-7271
MAIL ADDRESS:
STREET 1: 2800 DISCOVERY DRIVE
STREET 2: SUITE 100
CITY: ORLANDO
STATE: FL
ZIP: 32826
FORMER COMPANY:
FORMER CONFORMED NAME: LensAR Inc
DATE OF NAME CHANGE: 20070703
FORMER COMPANY:
FORMER CONFORMED NAME: LaserSoft Vision Inc
DATE OF NAME CHANGE: 20050310
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-25
0
0001320350
LENSAR, Inc.
LNSR
0001277967
MCLAUGHLIN JOHN PETER
C/O LENSAR, INC.
2800 DISCOVERY DRIVE
ORLANDO
FL
32826
1
0
0
0
Common Stock
2022-05-25
4
A
0
4285
0.00
A
44343
D
Stock Option (Right to Buy)
7.00
2022-05-25
4
A
0
15616
0.00
A
2032-05-25
Common Stock
15616
15616
D
Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2023, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer
Includes 40,058 shares of the Issuer's common stock received by the Reporting Person in connection with the October 1, 2020 spin-off (the "Spin-Off Date") of the Issuer from PDL BioPharma, Inc. ("PDL") on account of his ownership of shares of PDL common stock.
The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
/s/ Thomas R. Staab, II, attorney-in-fact
2022-05-27